The mechanism of cancer-mediated conversion of plasmangiogenesis hibitor ngiostatin

Proceedings of the National Academy of Sciences of the Unite 94, 10868-10872

DOI: 10.1073/pnas.94.20.10868

Citation Report

#	Article	IF	CITATIONS
1	Angiostatin-converting Enzyme Activities of Human Matrilysin (MMP-7) and Gelatinase B/Type IV Collagenase (MMP-9). Journal of Biological Chemistry, 1997, 272, 28823-28825.	3.4	367
2	Angiogenesis antagonists: current clinical trials. , 1998, 2, 9-20.		18
3	Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature, 1998, 394, 287-291.	27.8	629
5	Expression of human macrophage metalloelastase gene in hepatocellular carcinoma: Correlation with angiostatin generation and its clinical significance. Hepatology, 1998, 28, 986-993.	7.3	78
6	Wound Fluid from Venous Leg Ulcers Degrades Plasminogen and Reduces Plasmin Generation by Keratinocytes. Journal of Investigative Dermatology, 1998, 111, 1140-1144.	0.7	34
7	Are angiostatin and endostatin cures for cancer?. Lancet, The, 1998, 351, 1598-1599.	13.7	34
8	Transforming growth factor–beta1 inhibits generation of angiostatin by human pancreatic cancer cells. Surgery, 1998, 124, 388-393.	1.9	33
9	Selective Inhibition by Kringle 5 of Human Plasminogen on Endothelial Cell Migration, an Important Process in Angiogenesis. Biochemical and Biophysical Research Communications, 1998, 247, 414-419.	2.1	90
10	A Novel Assay of Angiogenesis in the Quail Chorioallantoic Membrane: Stimulation by bFGF and Inhibition by Angiostatin According to Fractal Dimension and Grid Intersection. Microvascular Research, 1998, 55, 201-214.	2.5	113
11	Generation of an Angiostatin-like Fragment from Plasminogen by Stromelysin-1 (MMP-3). Biochemistry, 1998, 37, 4699-4702.	2.5	187
12	Prothrombin Kringle-2 Domain Has a Growth Inhibitory Activity against Basic Fibroblast Growth Factor-stimulated Capillary Endothelial Cells. Journal of Biological Chemistry, 1998, 273, 28805-28812.	3.4	77
13	Macrophage Formation of Angiostatin during Inflammation. Journal of Biological Chemistry, 1998, 273, 31480-31485.	3.4	51
14	Angiostatin-mediated Suppression of Cancer Metastases by Primary Neoplasms Engineered to Produce Granulocyte/Macrophage Colony–stimulating Factor. Journal of Experimental Medicine, 1998, 188, 755-763.	8.5	78
15	Characterization of kringle domains of angiostatin as antagonists of endothelial cell migration, an important process in angiogenesis. FASEB Journal, 1998, 12, 1731-1738.	0.5	123
16	Prolonged neoadjuvant treatment in locally advanced tumours: A novel concept based on biological considerations. Annals of Oncology, 1999, 10, 155-160.	1.2	10
17	Matrix Metalloproteinase System Deficiencies and Matrix Degradation. Thrombosis and Haemostasis, 1999, 82, 837-845.	3.4	142
18	The Role of the Plasminogen Activation System in Cancer. Seminars in Thrombosis and Hemostasis, 1999, 25, 183-197.	2.7	64
19	Angiostatin Diminishes Activation of the Mitogen-Activated Protein Kinases ERK-1 and ERK-2 in Human Dermal Microvascular Endothelial Cells. Iournal of Vascular Research. 1999. 36. 28-34.	1.4	82

#	Article	IF	CITATIONS
20	Angiostatin Formation Involves Disulfide Bond Reduction and Proteolysis in Kringle 5 of Plasmin. Journal of Biological Chemistry, 1999, 274, 8910-8916.	3.4	78
21	Angiogenesis Activators and Inhibitors Differentially Regulate Caveolin-1 Expression and Caveolae Formation in Vascular Endothelial Cells. Journal of Biological Chemistry, 1999, 274, 15781-15785.	3.4	151
22	Angiostatin binds ATP synthase on the surface of human endothelial cells. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 2811-2816.	7.1	474
23	Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen. British Journal of Cancer, 1999, 81, 1269-1273.	6.4	123
24	Antisense RNA gene therapy for studying and modulating biological processes. Cellular and Molecular Life Sciences, 1999, 55, 334-358.	5.4	99
25	The urokinase plasminogen activator system in cancer: implications for tumor angiogenesis and metastasis. Angiogenesis, 1999, 3, 15-32.	7.2	150
26	Role of carbohydrate on angiostatin in the treatment of cancer. Translational Research, 1999, 134, 553-560.	2.3	10
27	Homeostatic control of angiogenesis: A newly identified function of the liver?. Hepatology, 1999, 29, 621-623.	7.3	36
28	Future prospects in prostate cancer. Prostate, 1999, 40, 261-268.	2.3	40
29	Diurnal variations in angiostatin in human tear fluid: A possible role in prevention of corneal neovascularization. Current Eye Research, 1999, 18, 186-193.	1.5	41
30	Regulation of cancer invasion and vascularization by plasminogen activator inhibitor-1. Fibrinolysis and Proteolysis, 1999, 13, 220-225.	1.1	16
31	The Rationale and Future Potential of Angiogenesis Inhibitors in Neoplasia. Drugs, 1999, 58, 17-38.	10.9	150
32	Kringle 5 Causes Cell Cycle Arrest and Apoptosis of Endothelial Cells. Biochemical and Biophysical Research Communications, 1999, 258, 668-673.	2.1	74
33	The Tumor-Suppressing Activity of Angiostatin Protein Resides within Kringles 1 to 3. Biochemical and Biophysical Research Communications, 1999, 264, 469-477.	2.1	49
34	Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation. Biochemical Journal, 1999, 340, 77-84.	3.7	101
35	Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation. Biochemical Journal, 1999, 340, 77.	3.7	50
36	Angiogenesis and Cancer Control: From Concept to Therapeutic Trial. Cancer Control, 1999, 6, 1-18.	1.8	104
37	Morphological Observations on Antitumor Activities of 70kDa Fragment in .ALPHASubunit from Pronase-Treated Ovomucin in a Double Grafted Tumor System Food Science and Technology Research, 2000. 6, 179-185	0.6	17

#	Article	IF	CITATIONS
38	Angiostatin generation by human tumor cell lines: Involvement of plasminogen activators. , 2000, 86, 760-767.		49
39	Matrix Metalloproteinases: Pro- and Anti-Angiogenic Activities. Journal of Investigative Dermatology Symposium Proceedings, 2000, 5, 47-54.	0.8	95
40	A novel strategy for the tumor angiogenesis-targeted gene therapy: Generation of angiostatin from endogenous plasminogen by protease gene transfer. Cancer Gene Therapy, 2000, 7, 589-596.	4.6	29
41	Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene, 2000, 19, 6122-6129.	5.9	237
42	Differentially Expressed Genes in Two LNCaP Prostate Cancer Cell Lines Reflecting Changes during Prostate Cancer Progression. Laboratory Investigation, 2000, 80, 1259-1268.	3.7	95
43	Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase. Nature, 2000, 408, 869-873.	27.8	264
44	Rapid exchange of histone H1.1 on chromatin in living human cells. Nature, 2000, 408, 873-876.	27.8	397
45	Towards a closed eye model of the pre-ocular tear layer. Progress in Retinal and Eye Research, 2000, 19, 649-668.	15.5	127
46	Angiogenesis and Surgery: from Mice to Man. The European Journal of Surgery, 2000, 166, 435-446.	0.9	8
47	Angiostatin and angiostatin-related proteins. Cancer and Metastasis Reviews, 2000, 19, 97-107.	5.9	100
48	The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer and Metastasis Reviews, 2000, 19, 19-27.	5.9	314
49	The plasminogen activation system in tumor growth, invasion, and metastasis. Cellular and Molecular Life Sciences, 2000, 57, 25-40.	5.4	864
50	Angiogenesis in malignant primary and metastatic brain tumors. Journal of Neurology, 2000, 247, 597-608.	3.6	53
51	Time-Dependent Relevance of Steroid Receptors in Breast Cancer. Journal of Clinical Oncology, 2000, 18, 2702-2709.	1.6	47
52	Proteinase-activated Receptor-1 Regulation of Macrophage Elastase (MMP-12) Secretion by Serine Proteinases. Journal of Biological Chemistry, 2000, 275, 41243-41250.	3.4	72
53	Angiostatin Generation by Cathepsin D Secreted by Human Prostate Carcinoma Cells. Journal of Biological Chemistry, 2000, 275, 38912-38920.	3.4	77
54	Angiogenesis in the thyroid gland. Journal of Endocrinology, 2000, 166, 475-480.	2.6	125
55	Disruption of Interkringle Disulfide Bond of Plasminogen Kringle 1-3 Changes the Lysine Binding Capability of Kringle 2, but Not Its Antiangiogenic Activity. Archives of Biochemistry and Biophysics, 2000, 375, 359-363.	3.0	8

#	Article	IF	CITATIONS
56	Human Glioma Cell BT325 Expresses a Proteinase That Converts Human Plasminogen to Kringle 1–5-Containing Fragments. Biochemical and Biophysical Research Communications, 2000, 278, 821-825.	2.1	9
57	Molecular interactions between the plasminogen/plasmin and matrix metalloproteinase systems. Fibrinolysis and Proteolysis, 2000, 14, 175-181.	1.1	42
58	Tissue factor expression and multidrug resistance in cancer: two aspects of a common cellular response to a hostile milieu. Medical Hypotheses, 2000, 55, 470-473.	1.5	16
59	The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. European Journal of Cancer, 2000, 36, 151-169.	2.8	185
60	The Hallmarks of Cancer. Cell, 2000, 100, 57-70.	28.9	24,832
61	Angiogenesis and non-small cell lung cancer. Lung Cancer, 2000, 27, 81-100.	2.0	88
62	Specific Proteolysis of Human Plasminogen by a 24 kDa Endopeptidase from a Novel Chryseobacterium Sp Biochemistry, 2000, 39, 479-488.	2.5	24
64	Adenoviral Vector Expressing Murine Angiostatin Inhibits a Model of Breast Cancer Metastatic Growth in the Lungs of Mice. American Journal of Pathology, 2001, 159, 1137-1147.	3.8	33
65	Enzyme-Linked Immunosorbent Assay for the Specific Detection of Angiostatin-Like Plasminogen Moieties in Biological Samples. Thrombosis Research, 2001, 102, 53-59.	1.7	6
66	Matrix Metalloproteinase Deficiencies Do Not Impair Cell-Associated Fibrinolytic Activity. Thrombosis Research, 2001, 102, 61-69.	1.7	18
67	Endothelial cell surface F ₁ -F _O ATP synthase is active in ATP synthesis and is inhibited by angiostatin. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 6656-6661.	7.1	298
68	Effect of external ocular surgery and mode of post-operative care on plasminogen, plasmin, angiostatins and a2-macroglobulin in tears. Current Eye Research, 2001, 22, 286-294.	1.5	12
69	Blood Vessels are Regulators of Growth, Diagnostic Markers and Therapeutic Targets in Prostate Cancer. Scandinavian Journal of Urology and Nephrology, 2001, 35, 437-452.	1.4	60
70	Extracellular Proteolysis and Angiogenesis. Thrombosis and Haemostasis, 2001, 86, 346-355.	3.4	166
71	Functional Evaluation of Plasmin Formation in Primary Breast Cancer. Journal of Clinical Oncology, 2001, 19, 2731-2738.	1.6	33
72	Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. FASEB Journal, 2001, 15, 1021-1027.	0.5	98
73	Progress in studies of angiostatin and its anti-tumor effects. Science Bulletin, 2001, 46, 454-459.	1.7	0
74	Development of a synthetic cyclized peptide derived from α-fetoprotein that prevents the growth of human breast cancer. Chemical Biology and Drug Design, 2001, 58, 246-256.	1.1	35

ARTICLE IF CITATIONS # Pharmacokinetics and whole body distribution of elastase derived angiostatin(k1-3) in rats. 75 5.1 13 International Journal of Cancer, 2001, 91, 1-7. The urokinase-type plasminogen activator system in prostate cancer metastasis. Cancer and Metastasis Reviews, 2001, 20, 287-296. Angiogenesis in prostate cancer: biology and therapeutic opportunities. Cancer and Metastasis 77 5.9 37 Reviews, 2001, 20, 297-319. Metabolism of rabbit angiostatin glycoforms I and II in rabbits: Angiostatin-I leaves the intravascular space faster and appears to have greater anti-angiogenic activity than angiostatin-II. Translational Research, 2001, 138, 83-93. Purification and Characterization of A61. Journal of Biological Chemistry, 2001, 276, 8924-8933. 79 3.4 35 A Truncated Plasminogen Activator Inhibitor-1 Protein Induces and Inhibits Angiostatin (Kringles 1 \hat{a} \in "3), 3.4 a Plasminogen Cleavage Product. Journal of Biological Chemistry, 2001, 276, 8588-8596. 81 Familiar drugs may prevent cancer. Postgraduate Medical Journal, 2001, 77, 492-497. 1.8 4 Hold That Line. Journal of Cell Biology, 2001, 152, F35-F36. 5.2 10 83 Antiangiogenic Approaches to Renal Cell Carcinoma. Methods in Molecular Medicine, 2001, 53, 277-298. 0.8 1 Tumour angiogenesis: a novel therapeutic target in patients with malignant disease. Expert Opinion on 84 1.1 Emerging Drugs, 2001, 6, 155-174. Plasmin-induced Migration of Endothelial Cells. Journal of Biological Chemistry, 2002, 277, 85 3.4 117 33564-33570. Generation of Biologically Active Angiostatin Kringle 1–3 by Activated Human Neutrophils. Journal of 0.8 86 Immunology, 2002, 168, 5798-5804. Plasmin Reduction by Phosphoglycerate Kinase Is a Thiol-independent Process. Journal of Biological 87 3.4 35 Chemistry, 2002, 277, 9062-9068. Identification of Annexin II Heterotetramer as a Plasmin Reductase. Journal of Biological Chemistry, 3.4 2002, 277, 10903-10911. Inhibition of Tumor Angiogenesis by Angiostatin: From Recombinant Protein to Gene Therapy. 89 1.7 37 Endothelium: Journal of Endothelial Cell Research, 2002, 9, 3-10. Biological regulation through protein disulfide bond cleavage. Redox Report, 2002, 7, 71-77. Thyroid follicular cells secrete plasminogen activators and can form angiostatin from plasminogen. 91 2.6 16 Journal of Endocrinology, 2002, 173, 475-481. Perindopril: possible use in cancer therapy. Anti-Cancer Drugs, 2002, 13, 221-228. 1.4

#	Article	IF	CITATIONS
94	Plasminogen activator inhibitor-1 and the kidney. American Journal of Physiology - Renal Physiology, 2002, 283, F209-F220.	2.7	166
95	The Role of Angiostatin in the Spontaneous Bone and Prostate Cancers of Pet Dogs. Biochemical and Biophysical Research Communications, 2002, 292, 886-891.	2.1	11
96	â€~Angioprevention': angiogenesis is a common and key target for cancer chemopreventive agents. FASEB Journal, 2002, 16, 2-14.	0.5	309
97	Coagulation, angiogenesis, and venous thromboembolism in cancer. Lancet, The, 2002, 359, 1440.	13.7	3
98	The X-ray Crystallographic Structure of the Angiogenesis Inhibitor Angiostatin. Journal of Molecular Biology, 2002, 318, 1009-1017.	4.2	35
99	Radiation-induced tumour necrosis factor- $\hat{I}\pm$ expression: clinical application of transcriptional and physical targeting of gene therapy. Lancet Oncology, The, 2002, 3, 665-671.	10.7	80
100	Anti-angiogenic agents for the treatment of brain tumors. Neuroimaging Clinics of North America, 2002, 12, 477-499.	1.0	13
101	The Mechanism of Action of Angiostatin: Can You Teach an Old Dog New Tricks?. Thrombosis and Haemostasis, 2002, 87, 394-401.	3.4	27
102	Soluble Tissue Factor Interferes with Angiostatin-mediated Inhibition of Endothelial Cell Proliferation by Lysine-specific Interaction with Plasminogen Kringle Domains. Thrombosis and Haemostasis, 2002, 88, 1054-1059.	3.4	12
103	Angiostatin II is the predominant glycoform in pleural effusates of rabbit VX-2 lung tumors. Translational Research, 2002, 139, 316-323.	2.3	11
104	Differential production of angiostatin by concomitant antitumoral resistance-inducing cancer cells. International Journal of Cancer, 2002, 100, 14-21.	5.1	8
105	Inhibition of spontaneous metastases formation by amifostine. International Journal of Cancer, 2002, 97, 135-141.	5.1	24
106	Tumor production of angiostatin is enhanced after exposure to TNF-?. International Journal of Cancer, 2002, 97, 410-415.	5.1	25
107	Cyclooxygenase, lipoxygenase and tumor angiogenesis. Cellular and Molecular Life Sciences, 2002, 59, 799-807.	5.4	136
108	Molecular targets in the inhibition of angiogenesis. Expert Opinion on Therapeutic Targets, 2003, 7, 527-541.	3.4	10
109	Tumor angiogenesis inhibitors. Biochemistry (Moscow), 2003, 68, 497-513.	1.5	3
110	Angiostatin and hepatocellular carcinoma. Hepatology, 2003, 37, 505-506.	7.3	3
111	Intraoperative TEE for the management of pulmonary tumour embolism during chondroblastic osteosarcoma resection. Canadian Journal of Anaesthesia, 2003, 50, 886-890.	1.6	19

#	Article	IF	CITATIONS
112	Role of plasminogen activator-plasmin system in tumor angiogenesis. Cellular and Molecular Life Sciences, 2003, 60, 463-473.	5.4	108
113	Disulfide bonds as switches for protein function. Trends in Biochemical Sciences, 2003, 28, 210-214.	7.5	530
114	Different inhibitors of plasmin differentially affect angiostatin production and angiogenesis. European Journal of Pharmacology, 2003, 460, 1-8.	3.5	16
115	Angiogenic proteins in brains of patients who died with cerebral malaria. Journal of Neuroimmunology, 2003, 142, 101-111.	2.3	44
116	Vascular smooth muscle cells efficiently activate a new proteinase cascade involving plasminogen and fibronectin. Journal of Cellular Biochemistry, 2003, 88, 1188-1201.	2.6	23
117	Cloning, expression and in vitro evaluation of recombinant canine Tum5, an angiostatic domain of mammalian type IV collagen. Veterinary and Comparative Oncology, 2003, 1, 36-47.	1.8	2
118	Angiogenesis as a new target for cancer control. European Journal of Cancer, Supplement, 2003, 1, 1-12.	2.2	22
119	Anti-angiogenic, antioxidant and xanthine oxidase inhibition activities of the mushroom Phellinus linteus. Journal of Ethnopharmacology, 2003, 88, 113-116.	4.1	135
120	Infection and cancer: the common vein. Cytokine and Growth Factor Reviews, 2003, 14, 67-77.	7.2	31
121	Antiangiogenesis. , 2003, , 1279-1295.		1
122	Isolation and characterization of human thyroid endothelial cells. American Journal of Physiology - Endocrinology and Metabolism, 2003, 284, E168-E176.	3.5	27
123	In Vitro and In Vivo Induction of Antiangiogenic Activity by Plasminogen Activators and Captopril. Journal of the National Cancer Institute, 2003, 95, 388-399.	6.3	55
124	Hemostatic Regulators of Tumor Angiogenesis: A Source of Antiangiogenic Agents for Cancer Treatment?. Journal of the National Cancer Institute, 2003, 95, 1660-1673.	6.3	79
125	Tumour-Induced Angiogenesis: A Review. Journal of Theoretical Medicine, 2003, 5, 137-153.	0.5	33
126	A reinforced random walk model of tumour angiogenesis and anti-angiogenic strategies. Mathematical Medicine and Biology, 2003, 20, 135-181.	1.2	100
127	Antiangiogenic Cancer Therapy with Microencapsulated Cells. Human Gene Therapy, 2003, 14, 1065-1077.	2.7	50
129	Angiogenesis in Endocrine Tumors. Endocrine Reviews, 2003, 24, 600-632.	20.1	251
130	Cyclooxygenase-2 Overexpression Inhibits Cathepsin D-Mediated Cleavage of Plasminogen to the Potent Antiangiogenic Factor Angiostatin. Endocrinology, 2003, 144, 5322-5328.	2.8	21

	CITATION	Report	
#	ARTICLE	IF	CITATIONS
131	merapeutic Strategies using inhibitors of Anglogenesis. , 2005, 225, 599-654.		4
132	Therapeutic Potential of Selective Cyclooxygenase-2 Inhibitors in the Management of Tumor Angiogenesis. , 2003, 37, 179-192.		103
133	Angiostatin selectively inhibits signaling by hepatocyte growth factor in endothelial and smooth muscle cells. Blood, 2003, 101, 1857-1863.	1.4	61
134	Generation and role of angiostatin in human platelets. Blood, 2003, 102, 3217-3223.	1.4	58
135	Regulation of angiogenesis by the hemostatic system. Frontiers in Bioscience - Landmark, 2003, 8, d286-293.	3.0	7
136	Tetranectin Binds to the Kringle 1-4 Form of Angiostatin and Modifies Its Functional Activity. Journal of Biomedicine and Biotechnology, 2004, 2004, 73-78.	3.0	33
137	The Fibrinolytic System and Matrix Metalloproteinases in Angiogenesis and Tumor Progression. Seminars in Thrombosis and Hemostasis, 2004, 30, 71-82.	2.7	19
138	Angiostatin. Seminars in Thrombosis and Hemostasis, 2004, 30, 83-93.	2.7	74
139	Cell Surface-Dependent Generation of Angiostatin4.5. Cancer Research, 2004, 64, 162-168.	0.9	35
140	Progress Report on the Potential of Angiogenesis Inhibitors for Neuro-Oncology. Cancer Investigation, 2004, 22, 577-587.	1.3	19
141	Plasmin-induced Migration Requires Signaling through Protease-activated Receptor 1 and Integrin α9β1. Journal of Biological Chemistry, 2004, 279, 37528-37534.	3.4	71
142	Angiotensin converting enzyme inhibitors for cancer treatment?. Acta Oncológica, 2004, 43, 142-152.	1.8	67
143	What the structure of angiostatin may tell us about its mechanism of action. Journal of Thrombosis and Haemostasis, 2004, 2, 23-34.	3.8	36
144	Tumor growth and metastasis are not affected in thrombin-activatable fibrinolysis inhibitor-deficient mice. Journal of Thrombosis and Haemostasis, 2004, 2, 769-779.	3.8	19
145	Synergistic antitumor effect of antiangiogenic factor genes on colon 26 produced by low-voltage electroporation. Cancer Gene Therapy, 2004, 11, 625-632.	4.6	17
146	Plasminogen fragmentation and increased production of extracellular matrix-degrading proteinases are associated with serous epithelial ovarian cancer progression. Gynecologic Oncology, 2004, 92, 80-88.	1.4	28
147	Antiinflammatory effects of genipin, an active principle of gardenia. European Journal of Pharmacology, 2004, 495, 201-208.	3.5	254
148	Angiogenic and antiangiogenic balance regulates concomitant antitumoral resistance. Clinical and Experimental Metastasis, 2004, 21, 177-183.	3.3	14

#	ARTICLE	IF	CITATIONS
149	xenograft model. International Journal of Cancer, 2004, 112, 329-334.	5.1	29
150	Angiogenesis and prostate cancer tumor growth. Journal of Cellular Biochemistry, 2004, 91, 125-150.	2.6	110
151	The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Critical Reviews in Oncology/Hematology, 2004, 50, 87-100.	4.4	308
152	Kringle 5 peptide–albumin conjugates with anti-migratory activity. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 841-845.	2.2	17
153	Antiangiogenic therapy for primary and metastatic brain tumors. Hematology/Oncology Clinics of North America, 2004, 18, 1161-1181.	2.2	20
154	Captopril suppresses Post-transplantation angiogenic activity in rat allograft coronary vessels. Journal of Heart and Lung Transplantation, 2004, 23, 666-673.	0.6	8
155	Characterization and biological activities of recombinant human plasminogen kringle 1–3 produced in Escherichia coli. Protein Expression and Purification, 2004, 36, 1-10.	1.3	4
156	N-Acetyl-Cysteine Promotes Angiostatin Production and Vascular Collapse in an Orthotopic Model of Breast Cancer. American Journal of Pathology, 2004, 164, 1683-1696.	3.8	62
157	Anti-angiogenic and inhibitory activity on inducible nitric oxide production of the mushroom Ganoderma lucidum. Journal of Ethnopharmacology, 2004, 90, 17-20.	4.1	76
158	Anti-inflammatory and related pharmacological activities of the n-BuOH subfraction of mushroom Phellinus linteus. Journal of Ethnopharmacology, 2004, 93, 141-146.	4.1	96
159	Elevated levels of angiostatin in effusions from patients with malignant disease. Oncology Reports, 2004, 11, 523.	2.6	2
160	Angiostatin. , 2005, 126, 175-204.		9
161	Single intratumoral injection of long-acting benzyl ester of D-penicillamine inhibits the growth of melanoma tumor in mice. Anti-Cancer Drugs, 2005, 16, 757-762.	1.4	4
162	Inhibition of breast adenocarcinoma growth by intratumoral injection of lipophilic long-acting lathyrogens. Anti-Cancer Drugs, 2005, 16, 201-210.	1.4	17
163	Angiostatin is a novel anti-inflammatory factor by inhibiting leukocyte recruitment. Blood, 2005, 105, 1036-1043.	1.4	74
164	Coley's toxin revisited: immunotherapy or plasminogen activator therapy of cancer?. Journal of Thrombosis and Haemostasis, 2005, 3, 424-427.	3.8	50
165	Angiogenesis and cerebral neoplasia. Veterinary and Comparative Oncology, 2005, 3, 123-138.	1.8	3
166	A multiprong approach to cancer gene therapy by coencapsulated cells. Cancer Gene Therapy, 2005, 12, 369-380.	4.6	16

#	Article	IF	CITATIONS
167	Inhibition of endothelial cell movement and tubulogenesis by human recombinant soluble melanotransferrin: involvement of the u-PAR/LRP plasminolytic system. Biochimica Et Biophysica Acta - Molecular Cell Research, 2005, 1743, 243-253.	4.1	17
168	Reduction of myocardial infarct size by doxycycline: A role for plasmin inhibition. Molecular and Cellular Biochemistry, 2005, 270, 1-11.	3.1	43
169	S100A10, annexin A2, and annexin a2 heterotetramer as candidate plasminogen receptors. Frontiers in Bioscience - Landmark, 2005, 10, 300.	3.0	153
170	Angiogenesis in Benign and Malignant Thyroid Disease. Thyroid, 2005, 15, 494-510.	4.5	24
171	Biochemical and Enzymatic Characterization of Human Kallikrein 5 (hK5), a Novel Serine Protease Potentially Involved in Cancer Progression. Journal of Biological Chemistry, 2005, 280, 14628-14635.	3.4	137
172	In vivo Generation of Angiostatin Isoforms by Administration of a Plasminogen Activator and a Free Sulfhydryl Donor: A Phase I Study of an Angiostatic Cocktail of Tissue Plasminogen Activator and Mesna. Clinical Cancer Research, 2005, 11, 6218-6225.	7.0	25
173	Synthesis and Evaluation of Long-Acting D-Penicillamine Derivatives. Connective Tissue Research, 2005, 46, 242-250.	2.3	11
174	Stimulation of cell surface plasminogen activation by membrane-bound melanotransferrin: A key phenomenon for cell invasion. Experimental Cell Research, 2005, 308, 479-490.	2.6	15
175	Future Innovations in Treating Advanced Prostate Cancer. Urologic Clinics of North America, 2006, 33, 247-272.	1.8	3
176	Current status of anti-angiogenesis therapy for prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2006, 24, 260-268.	1.6	17
177	Generation of platelet angiostatin mediated by urokinase plasminogen activator: effects on angiogenesis. Journal of Thrombosis and Haemostasis, 2006, 4, 1095-1106.	3.8	41
178	Eicosanoid Regulation of Angiogenesis in Human Prostate Carcinoma and Its Therapeutic Implications. Annals of the New York Academy of Sciences, 2000, 905, 165-176.	3.8	21
179	Angiostatin generating capacity and anti-tumour effects of D-penicillamine and plasminogen activators. BMC Cancer, 2006, 6, 149.	2.6	6
180	Tumor shedding of laminin binding protein modulates angiostatin productionin vitro and interferes with plasmin-derived inhibition of angiogenesis in aortic ring cultures. International Journal of Cancer, 2006, 118, 2421-2432.	5.1	6
181	Protease Activity of Urokinase and Tumor Progression in a Syngeneic Mammary Cancer Model. Journal of the National Cancer Institute, 2006, 98, 756-764.	6.3	13
182	Immuno-Isolation in Cancer Gene Therapy. Current Gene Therapy, 2006, 6, 181-191.	2.0	13
183	Differential Binding of Plasminogen, Plasmin, and Angiostatin4.5 to Cell Surface β-Actin: Implications for Cancer-Mediated Angiogenesis. Cancer Research, 2006, 66, 7211-7215.	0.9	26
184	Iodide Inhibits Vascular Endothelial Growth Factor-A Expression in Cultured Human Thyroid Follicles: A Microarray Search for Effects of Thyrotropin and Iodide on Angiogenesis Factors. Thyroid, 2006, 16, 545-554.	4.5	39

#	Article	IF	CITATIONS
185	The Renin Angiotensin System in the Regulation of Angiogenesis. Current Pharmaceutical Design, 2007, 13, 1215-1229.	1.9	55
186	Plasmin-Cleaved β-2-Glycoprotein 1 Is an Inhibitor of Angiogenesis. American Journal of Pathology, 2007, 171, 1659-1669.	3.8	33
187	Alternatively spliced human tissue factor promotes tumor growth and angiogenesis in a pancreatic cancer tumor model. Thrombosis Research, 2007, 120, S13-S21.	1.7	81
188	Apoptosis, Senescence, and Cancer. , 2007, , .		8
189	The Plasminogen Activator System and Cancer. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2007, 36, 184-194.	0.3	131
190	The history of the angiogenic switch concept. Leukemia, 2007, 21, 44-52.	7.2	207
191	Tumor interstitial fluid pressure may regulate angiogenic factors in osteosarcoma. Journal of Orthopaedic Research, 2008, 26, 1520-1525.	2.3	41
192	Tissue-type plasminogen activator has antiangiogenic properties without effect on tumor growth in a rat C6 glioma model. Cancer Gene Therapy, 2008, 15, 685-692.	4.6	10
194	AFPep, a novel drug for the prevention and treatment of breast cancer, does not disrupt the estrous cycle or fertility in rats. Oncology Reports, 2009, 22, 49-56.	2.6	11
195	Live-cell imaging demonstrates extracellular matrix degradation in association with active cathepsin B in caveolae of endothelial cells during tube formation. Experimental Cell Research, 2009, 315, 1234-1246.	2.6	105
196	Impact of plasminogen on an in vitro wound healing model based on a perfusion cell culture system. Molecular and Cellular Biochemistry, 2009, 322, 1-13.	3.1	14
197	Melanoma incidence and exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Cancer Epidemiology, 2009, 33, 391-395.	1.9	21
198	Angiogenesis and hypertension: an update. Journal of Human Hypertension, 2009, 23, 773-782.	2.2	69
201	Nicked β2-glycoprotein I binds angiostatin 4.5 (plasminogen kringle 1-5) and attenuates its antiangiogenic property. Blood, 2009, 114, 2553-2559.	1.4	23
202	The cytoprotective drug amifostine modifies both expression and activity of the pro-angiogenic factor VEGF-A. BMC Medicine, 2010, 8, 19.	5.5	20
203	Pathophysiology of β2-glycoprotein I in antiphospholipid syndrome. Lupus, 2010, 19, 379-384.	1.6	27
204	Concept, mechanisms and therapeutics of angiogenesis in cancer and other diseases. Journal of Pharmacy and Pharmacology, 2010, 55, 1045-1053.	2.4	58
205	Induction of the fibrinolytic system by cartilage extract mediates its antiangiogenic effect in mouse glioma. Microvascular Research, 2011, 82, 6-17.	2.5	11

#	Article	IF	CITATIONS
206	Thrombophilic-Type Placental Pathologies and Skeletal Growth Delay Following Maternal Administration of Angiostatin4.5 in Mice. Biology of Reproduction, 2011, 84, 505-513.	2.7	4
207	Proteolytically Derived Endogenous Angioinhibitors Originating from the Extracellular Matrix. Pharmaceuticals, 2011, 4, 1551-1577.	3.8	21
208	Potential Role of Kringle-Integrin Interaction in Plasmin and uPA Actions (A Hypothesis). Journal of Biomedicine and Biotechnology, 2012, 2012, 1-8.	3.0	4
209	Role of Plasminogen Activator Inhibitor-1 in Urokinase's Paradoxical <i>In Vivo</i> Tumor Suppressing or Promoting Effects. Molecular Cancer Research, 2012, 10, 1271-1281.	3.4	17
210	Tumor Angiogenesis as a Target for Dietary Cancer Prevention. Journal of Oncology, 2012, 2012, 1-23.	1.3	66
211	Platelet-associated angiogenesis regulating factors: a pharmacological perspective. Canadian Journal of Physiology and Pharmacology, 2012, 90, 679-688.	1.4	41
212	Circulating Angiostatin, bFGF, and Tie2/TEK Levels and Their Prognostic Impact in Bladder Cancer. Urology, 2012, 80, 737.e13-737.e18.	1.0	12
213	Addition of an induction regimen of antiangiogenesis and antitumor immunity to standard chemotherapy improves survival in advanced malignancies. Medical Oncology, 2012, 29, 3626-3633.	2.5	17
214	4.3 Plasmin and the plasminogen activator system in health and disease. , 2012, , 261-290.		5
215	MicroRNAs mediate metabolic stresses and angiogenesis. Cellular and Molecular Life Sciences, 2012, 69, 1049-1065.	5.4	20
216	D-penicillamine and other low molecular weight thiols: Review of anticancer effects and related mechanisms. Cancer Letters, 2013, 337, 8-21.	7.2	47
217	Human plasminogen kringle 1–5 inhibits angiogenesis and induces thrombomodulin degradation in a protein kinase A-dependent manner. Journal of Molecular and Cellular Cardiology, 2013, 63, 79-88.	1.9	12
218	Reduction of tumor angiogenesis induced by desmopressin in a breast cancer model. Breast Cancer Research and Treatment, 2013, 142, 9-18.	2.5	34
219	Role of uPA/uPAR in the Modulation of Angiogenesis. Chemical Immunology and Allergy, 2014, 99, 105-122.	1.7	49
220	Proteolytic Activity of Prostate-Specific Antigen (PSA) towards Protein Substrates and Effect of Peptides Stimulating PSA Activity. PLoS ONE, 2014, 9, e107819.	2.5	28
221	Pulmonary arteriovenous malformations after the superior cavopulmonary shunt: mechanisms and clinical implications. Expert Review of Cardiovascular Therapy, 2014, 12, 703-713.	1.5	47
223	Tissue-type plasminogen activator is not necessary for platelet-derived growth factor-c activation. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 318-325.	3.8	7
224	Blockade of the renin–angiotensin system inhibits growth of colorectal cancer liver metastases in the regenerating liver. Clinical and Experimental Metastasis, 2014, 31, 395-405.	3.3	34

#	Article	IF	CITATIONS
225	Mechanisms of vasculogenesis in 3D fibrin matrices mediated by the interaction of adipose-derived stem cells and endothelial cells. Angiogenesis, 2014, 17, 921-933.	7.2	114
226	Border patrol: Insights into the unique role of perlecan/heparan sulfate proteoglycan 2 at cell and tissue borders. Matrix Biology, 2014, 34, 64-79.	3.6	137
227	Plasminogen activators are involved in angiostatin generation in vivo in benign and malignant ovarian tumor cyst fluids. International Journal of Oncology, 2014, 44, 1394-1400.	3.3	9
228	In vivo Optical Imaging of Matrix Metalloproteinase Activity Detects Acute and Chronic Contact Hypersensitivity Reactions and Enables Monitoring of the Antiinflammatory Effects of <i>N</i> -Acetylcysteine. Molecular Imaging, 2015, 14, 7290.2014.00044.	1.4	5
229	A Hypothesis Concerning the Biphasic Dose-response of Tumors to Angiostatin and Endostatin. Dose-Response, 2015, 13, dose-response.1.	1.6	5
230	β2-Glycoprotein I Inhibits Vascular Endothelial Growth Factor-Induced Angiogenesis by Suppressing the Phosphorylation of Extracellular Signal-Regulated Kinase 1/2, Akt, and Endothelial Nitric Oxide Synthase. PLoS ONE, 2016, 11, e0161950.	2.5	9
231	The Role of Angiogenesis in the Persistence of Chemoresistance in Epithelial Ovarian Cancer. Reproductive Sciences, 2016, 23, 1484-1492.	2.5	15
232	<i>In vivo</i> tumor-suppressing and anti-angiogenic activities of a recombinant anti-CD3ε nanobody in breast cancer mice model. Immunotherapy, 2019, 11, 1555-1567.	2.0	10
233	Renin–angiotensin system inhibitor use and colorectal cancer risk and mortality: A dose–response meta analysis. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2020, 21, 147032031989564.	1.7	19
234	Remodeling the homeostasis of pro- and anti-angiogenic factors by Shenmai injection to normalize tumor vasculature for enhanced cancer chemotherapy. Journal of Ethnopharmacology, 2021, 270, 113770.	4.1	11
235	Role of Serine Proteases and their Inhibitors in Tumor Growth and Angiogenesis. Cancer Metastasis - Biology and Treatment, 2002, , 23-38.	0.1	1
236	The Role of Plasminogen-Plasmin System in Cancer. Cancer Treatment and Research, 2009, 148, 43-66.	0.5	123
237	The Coagulation System and Angiogenesis. Cancer Treatment and Research, 2009, 148, 67-80.	0.5	2
238	Plasmin Reductase. , 2003, , 121-133.		1
239	Mechanism of Angiostatin Formation from Plasminogen. , 2003, , 135-156.		4
240	Angiogenesis Switch Pathways. , 2008, , 239-256.		3
241	Plasminogen and Streptokinase. Handbook of Experimental Pharmacology, 2001, , 25-56.	1.8	2
242	Serpins in Angiogenesis. , 2013, , 101-118.		1

#	Article	IF	CITATIONS
243	Mast Cells and Tumours. , 2011, , 83-88.		2
244	Angiogenic Activity of Sera from Interstitial Lung Disease Patients in Relation to Angiotensin-Converting Enzyme Activity. Advances in Experimental Medicine and Biology, 2013, 756, 213-221.	1.6	5
245	Angiostatin. , 2001, , 139-141.		1
246	Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. FASEB Journal, 2001, 15, 1021-1027.	0.5	26
247	Anticancer drug targets: approaching angiogenesis. Journal of Clinical Investigation, 1999, 104, 1497-1501.	8.2	103
248	Antiangiogenic Gene Therapy in Cancer. Current Genomics, 2000, 1, 117-133.	1.6	7
249	Identification and Characterization of a Novel Angiostatin-binding Protein by the Display Cloning Method. BMB Reports, 2004, 37, 159-166.	2.4	8
250	Apoptosis, Angiogenesis and Cancer Therapies. Journal of Cancer Therapeutics & Research, 2012, 1, 3.	1.2	14
251	The Role of Angiogenesis in Breast Cancer Progression. , 2001, , 41-62.		0
252	Strategies for Combining Gene Therapy with Ionizing Radiation to Improve Antitumor Efficacy. , 2002, , 435-448.		1
253	Antiangiogenic Gene Therapy. , 2002, , 405-419.		0
254	Role of the Plasminogen Activator-Plasmin System in Angiogenesis. , 2003, , 269-290.		0
255	Tumor Angiogenesis as a Target for Early Intervention and Cancer Prevention. , 2004, , 611-633.		0
256	Zellinvasion und Metastasierung. , 2004, , 325-354.		0
259	Nicked β2-glycoprotein I binds angiostatin 4.5 and attenuates its anti-angiogenic property. Japanese Journal of Thrombosis and Hemostasis, 2010, 21, 314-318.	0.1	0
260	Emerging Groups of C-Type Lectins. , 2012, , 881-900.		Ο
261	Plasminogen and angiostatin levels in female benign breast lesions. Ukrainian Biochemical Journal, 2015, 87, 103-112.	0.5	1
262	Evaluate the response of Apoptosis, Angiogenesis and Cancer Therapies. Cancer Research and Cellular Therapeutics, 2018, 2, 01-08.	0.0	0

#	Article	IF	CITATIONS
263	The urokinase-type plasminogen activator system in prostate cancer metastasis. , 2002, , 151-160.		0
264	Angiogenesis in prostate cancer: Biology and therapeutic opportunities. , 2002, , 161-183.		9
266	Role of Apoptosis in Anti-Angiogenic Cancer Therapies. , 2007, , 537-555.		2
267	Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation. Biochemical Journal, 1999, 340 (Pt 1), 77-84.	3.7	19
268	Enzymatic function of multiple origins regulates the progression of colorectal cancer and the development of metastases. Hippokratia, 2009, 13, 23-31.	0.3	12
269	Inhibition of Nm23H2 gene product (NDPK-B) by angiostatin, polyphenols and nucleoside analogs. Proceedings of the Western Pharmacology Society, 2008, 51, 30-4.	0.1	18
271	Tranexamic acid reduces endometrial cancer effects through the production of angiostatin. Journal of Cancer, 2022, 13, 1603-1610.	2.5	6
272	Vasopressin and Its Analogues: From Natural Hormones to Multitasking Peptides. International Journal of Molecular Sciences, 2022, 23, 3068.	4.1	22
273	Progress in Isoindolone Alkaloid Derivatives from Marine Microorganism: Pharmacology, Preparation, and Mechanism. Marine Drugs, 2022, 20, 405.	4.6	9
274	Identification of PCSK9-like human gene knockouts using metabolomics, proteomics, and whole-genome sequencing in a consanguineous population. Cell Genomics, 2023, 3, 100218.	6.5	4
275	Tumour Interstitial Fluid Pressure May Regulate Angiogenic Factors in Osteosarcoma. Annals of the Academy of Medicine, Singapore, 2009, 38, 1041-1047.	0.4	8
276	Matrix Metalloproteinases Generate Angiostatin: Effects on Neovascularization. Journal of Immunology, 1998, 161, 6845-6852.	0.8	333
277	Weaving the nest: extracellular matrix roles in pre-metastatic niche formation. Frontiers in Oncology, 0, 13, .	2.8	4